Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments
摘要:
5-Hydroxy-3(2H)-pyridazinone derivatives were investigated as inhibitors of genotype 1 HCV NS5B polymerase. Lead optimization led to the discovery of compound 3a, which displayed potent inhibitory activities in biochemical and replicon assays [IC50 (1b) < 10 nM; IC50 (1a) = 22 nM; EC50 (1b) = 5 nM], good stability toward human liver microsomes (HLM t(1/2) > 60 min), and high ratios of liver to plasma concentrations 12 h after a single oral administration to rats. (c) 2008 Published by Elsevier Ltd.
Efficient synthesis of 2,6-disubstituted-5-hydroxy-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid ethyl esters
作者:Douglas E. Murphy、Peter S. Dragovich、Benjamin K. Ayida、Thomas M. Bertolini、Lian-Sheng Li、Frank Ruebsam、Nebojsa S. Stankovic、Zhongxiang Sun、Jingjing Zhao、Yuefen Zhou
DOI:10.1016/j.tetlet.2007.11.187
日期:2008.1
boxylic acidethylesters (6-substituted-5-hydroxy-3(2H)-pyridazinone-4-carboxylic acidethylesters). These compounds are shown to undergo selective alkylation at the 2-position in moderate to good yields (19–77%) to afford 2,6-disubstituted-5-hydroxy-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acidethylesters (2,6-disubstituted-5-hydroxy-3(2H)-pyridazinone-4-carboxylic acidethylesters).